Darunavir clinical pharmacology

Revision as of 16:31, 31 December 2013 by Ahmed Zaghw (talk | contribs)
Jump to navigation Jump to search
Darunavir
PREZISTA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]



References

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Darunavir_clinical_pharmacology&oldid=922140"